Biosimilar Revenue (Q4)
₹2,756 Cr
+12% YoY
Driven by advanced markets; sequential growth of 12% from Q3.
BIOCON
Other
15 May 2026
Biocon Limited — Q4 FY26
Biocon delivered a strong Q4 FY26, with adjusted revenue growth of 10% YoY and EBITDA up 29% YoY to ₹1,073 crore, driven by favorable mix and operating leverage in biosimilars.
✓ Verified against BSE filing
2-Min Summary
✦ AI-Generated from Full Transcript
Biocon delivered a strong Q4 FY26, with adjusted revenue growth of 10% YoY and EBITDA up 29% YoY to ₹1,073 crore, driven by favorable mix and operating leverage in biosimilars. The biosimilars segment grew 12% YoY with margins expanding to 26%, while generics (ex-lenalidomide) grew 13%. The integration of biosimilars and generics was completed in under 100 days, strengthening the balance sheet. Management highlighted that the heavy investment phase is behind, with focus shifting to execution and margin expansion. Key launches in FY27 include aflibercept (Yesafili) and insulin aspart (Kirsty), expected to ramp up in H2. Risks include potential pricing erosion in the US biosimilar market and competitive pressure from Chinese entrants in insulin.
Key Numbers
Insulin Franchise Revenue (FY26)
$300M+
+50% YoY
Crossed $300M; includes clargine, aspart, human insulin.
Adalimumab Revenue (FY26)
$250M+
+25% YoY
Global biosimilar adalimumab franchise.
Bevacizumab Market Share (US)
~25%
Flat YoY
Steady market share in US oncology medical benefit space.
Management Guidance
Biosimilar revenue growth of 16% in FY26 on like-to-like basis
Management expects continued growth in biosimilars, with new product launches scaling in H2 FY27.
Management guidance revenueEBITDA margin expansion of ~200bps in FY26 on like-to-like basis
Margins improved to 22% for FY26; management expects further operating leverage as new products ramp up.
Management guidance marginsNet debt reduction to ~$1.1B from $1.5B in March 2025
Free cash flow will be prioritized for deleveraging; interest cost savings of ~₹75 Cr per quarter expected.
Management guidance otherAflibercept (Yesafili) launch in US in H2 FY27
Settlement with originator allows entry; management expects meaningful revenue contribution from H2.
Management guidance growthKey Risks
Pricing erosion in US biosimilars
Competitive pressure and ASP declines in medical benefit products could impact margins.
medium · analyst_questionChinese competition in insulin
Recent Chinese approvals in insulin could disrupt pricing and market share.
medium · analyst_questionCRDMO revenue growth slowdown
Syngene's FY26 revenue grew only 3% YoY due to a large client impact; recovery uncertain.
medium · data_observationExecution risk on new product launches
Ramp-up of aspart and aflibercept depends on capacity qualification and market adoption.
low · management_commentaryNotable Quotes
We are now moving from a phase of integration and investment to one focused on execution, operating leverage, and value creation.
Growth is only when it's profitable. We've been very careful as we picked up market shares.
Every dollar that we generate out of free cash the first claim is going to be to reduce the debt.
Frequently Asked Questions
What was Biocon's revenue in Q4 FY26?
Biocon reported revenue of ₹4,517 Cr in Q4 FY26, representing a +10% change compared to the same quarter last year.
What guidance did Biocon management give for FY27?
Biosimilar revenue growth of 16% in FY26 on like-to-like basis: Management expects continued growth in biosimilars, with new product launches scaling in H2 FY27. EBITDA margin expansion of ~200bps in FY26 on like-to-like basis: Margins improved to 22% for FY26; management expects further operating leverage as new products ramp up. Net debt reduction to ~$1.1B from $1.5B in March 2025: Free cash flow will be prioritized for deleveraging; interest cost savings of ~₹75 Cr per quarter expected. Aflibercept (Yesafili) launch in US in H2 FY27: Settlement with originator allows entry; management expects meaningful revenue contribution from H2.
What are the key risks for Biocon in FY27?
Key risks include Pricing erosion in US biosimilars — Competitive pressure and ASP declines in medical benefit products could impact margins.; Chinese competition in insulin — Recent Chinese approvals in insulin could disrupt pricing and market share.; CRDMO revenue growth slowdown — Syngene's FY26 revenue grew only 3% YoY due to a large client impact; recovery uncertain.; Execution risk on new product launches — Ramp-up of aspart and aflibercept depends on capacity qualification and market adoption..
Did Biocon meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Biocon Q4 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary verified against official BSE/NSE filings.